Clinical trials: Psoriasis Patients
Psoriasis, Arthritis, Psoriatic
Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis
The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.
- Trial name
- NCT00161655
- Testing
- Etanercept, Methotrexate
- Where
- 8 sites in Denmark, Finland and 2 more
- Volunteers
- 60 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriasis
An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use
The purpose of this study is to evaluate the efficacy of re-treatment with etanercept 50mg subcutaneous injections twice weekly for 12 weeks in subjects who have previously been treated etanercept and efficacy diminished.
- Trial name
- ENBRECAP2009 (NCT01132235)
- Testing
- etanercept
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Florida Academic Dermatology Centers
Plaque Psoriasis
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
- Trial name
- IXORA-P (NCT02513550)
- Testing
- Ixekizumab
- Where
- 125 sites in United States, Argentina and 12 more
- Volunteers
- 1,257 people
- Sponsor
- Eli Lilly and Company
Healthy, Psoriasis
Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
The proposed exploratory study aims to understand the in vivo skin distribution properties of subcutaneously (s.c.) administered AIN457 in psoriatic and healthy skin using open flow microperfusion (OFM).
- Trial name
- OFM ISF (NCT01539213)
- Testing
- secukinumab (AIN457)
- Where
- Austria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Inflammatory Rheumatism
Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)
Janus kinase (JAK) inhibitors are a new class of molecules available to the therapeutic arsenal for chronic inflammatory rheumatic diseases.The tolerance profile of this new class needs to be better defined and its use in real…
- Conditions
- Rheumatoid Arthritis, Inflammatory Rheumatism, Psoriatic Arthritis, Spondyloarthritis
- Trial name
- MAJIK (NCT04602091)
- Testing
- no intervention
- Where
- 60 sites in France
- Volunteers
- 2,300 people
- Sponsor
- Societe Francaise de Rhumatologie
Psoriatic Arthritis, Upadacitinib
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life.
- Conditions
- Psoriatic Arthritis, Upadacitinib, Interleukin-17 Inhibitors
- Trial name
- UVIPWP (NCT07386717)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University First Hospital
Plaque Psoriasis
A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis
This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.
- Trial name
- NCT01634087
- Testing
- Itacitinib
- Where
- 9 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Incyte Corporation
Psoriasis
Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients .
To evaluate effect of acitretin versus Narrowband UVB on serum level of neopterin in psoriatic patients.
- Trial name
- NCT05401006
- Testing
- Acitretin 25Mg Cap, Narrowband ultraviolet B
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- South Valley University
Psoriasis
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
Safety, tolerability and efficacy of BI 655066 in male and female patients with moderate to severe psoriasis.
- Trial name
- NCT01577550
- Testing
- BI 655066 (very high i.v. dose), BI 655066 (high s.c. dose), BI 655066 (low i.v. dose)
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 39 people
- Sponsor
- AbbVie
Moderate to Severe Plaque Psoriasis
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of…
- Trial name
- NCT07051538
- Testing
- SHR-1139 Injections
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Psoriasis
Golimumab Plus UVB-311nm in Psoriasis
Golimumab, a TNF-alpha antibody, has been approved in the EC and USA for the treatment of psoriatic arthritis. The aim of this study is to determine in a randomized half-side comparison whether additional narrowband UVB-311nm…
- Trial name
- NCT01088698
- Testing
- UVB-311nm radiation
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Graz
Rheumatic Disease
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating…
- Trial name
- NCT07138898
- Testing
- Methotrexate, Sulfasalazine, Hydroxychloroquine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- NYU Langone Health
Psoriasis
Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis
Psoriasis, the most prevalent autoimmune disease in the U.S., manifests with plaque type psoriasis vulgaris with lesions localized to the scalp, postauricular region, face, diaper area, elbows, and knees.
- Trial name
- NCT03848806
- Testing
- HAT1, Calcipotriol
- Volunteers
- 174 people
- Sponsor
- Haus Bioceuticals
Psoriasis Vulgaris
Glucose Trnsporter and PEDF in Psoriasis
Psoriasis is a chronic relapsing cutaneous immune mediated inflammatory disease(IMID). In which there are skin lesions characterized by erythema, thickness and scale formation with different size from a pinhead to 20 cm in…
- Trial name
- NCT04242082
- Testing
- GLUT 1 gene expression
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Chronic Plaque Psoriasis
Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis
The study will evaluate the efficacy of cyclosporine at 2, 5 mg/kg/day bid (i.e. bis in a day), when administered twice a week compared to continuous administration, in patients with chronic plaque psoriasis.
- Trial name
- NCT00438360
- Testing
- Cyclosporine A microemulsion
- Where
- Italy
- Volunteers
- 243 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Inflammation
Subclinical Impairment of Cardiovascular System in Patients With Psoriasis
A cross-sectional study will be conducted, which will include 80 young patients with psoriasis, aged 30-45 years, treated with five different types of antipsoriatic treatment, and 20 healthy patients.
- Conditions
- Psoriasis, Inflammation, Endothelial Dysfunction, Metabolic Disturbance
- Trial name
- PaS (NCT05957120)
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- University Medical Centre Ljubljana
Psoriatic Arthritis, Spondyloarthritis, Axial
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)
- Trial name
- UP-SPOUT (NCT06454188)
- Testing
- Upadacitinib 15 MG [Rinvoq]
- Where
- 5 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- CARE ARTHRITIS LTD.
Psoriasis
Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept
Evaluate (i) safety of etanercept in patients with moderate to severe psoriasis in Spain; (ii) the incidence of adverse events reported in these patients, and (iii) the role that age and concomitant therapy might play in the…
- Trial name
- NCT00581165
- Testing
- Etanercept
- Volunteers
- 500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Arthritis, Psoriatic
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
The purpose of this study is to evaluate the effectiveness (improvement of signs and symptoms) and safety of ustekinumab in participants with active psoriatic arthritis.
- Trial name
- NCT01009086
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 102 sites in United States, Australia and 12 more
- Volunteers
- 615 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.